Rachael Brake

Rachael Brake, Ph.D., has successfully developed innovative drug discovery and clinical development oncology programs centered around patient-focused, unmet medical needs. Prior to joining Corbus in 2021, Dr. Brake most recently served at Takeda Pharmaceuticals where she held multiple leadership roles across the R&D continuum, including serving as Vice President, Global Project Leader in Oncology. In this position, she managed a portfolio of programs and cross-functional teams responsible for the preclinical and clinical exploration of various solid tumor drug candidates spanning diverse mechanisms of action. She is experienced in early- and late-stage clinical development, regulatory approvals (ALUNBRIG®, EXKIVITY™), program externalizations (DAY101, sapanisertib), and commercialization efforts. In her most recent role as the Head, of U.S. Medical Affairs, in the Oncology Business Unit, Dr. Brake developed a medical strategy for Takeda Oncology’s portfolio and emerging immune-focused pipeline. Prior to her tenure at Takeda, Dr. Brake held leadership roles in Research at Amgen Inc. and Millennium Pharmaceuticals, Inc. Dr. Brake obtained her Ph.D. in Molecular Biology and Biochemistry from the University of Western Australia Perth. She also received a Bachelor of Science from the Australian National University.